PDSB Stock Overview
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PDS Biotechnology Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.21 |
| 52 Week High | US$13.65 |
| 52 Week Low | US$2.89 |
| Beta | 1.62 |
| 1 Month Change | -10.79% |
| 3 Month Change | -4.40% |
| 1 Year Change | 71.38% |
| 3 Year Change | 122.65% |
| 5 Year Change | n/a |
| Change since IPO | -38.78% |
Recent News & Updates
Recent updates
PDS Biotech jumps 13% as FDA clears further development of lead asset
Oct 03PDS Biotechnology files for $150 mixed shelf offering
Aug 24PDS Biotech spikes as panel backs continuation of cancer trial for lead asset
Aug 04PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business
Jul 08
PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data
May 27PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers
Feb 22PDS Biotech: Looking Attractive Despite 52-Week High Price
Sep 19PDS Biotech under pressure after pricing equity offering at $8.50
Jun 15PDS Biotech announces preliminary efficacy readout from phase 2 combo trial of PDS0101
Feb 03PDS Biotechnology gives new CFO ~202K stock grant
Jan 06PDS Biotech launches mid-stage PDS0101 combo trial in head & neck cancer
Nov 10Shareholder Returns
| PDSB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.4% | -1.8% | -3.1% |
| 1Y | 71.4% | 10.3% | 15.1% |
Return vs Industry: PDSB exceeded the US Biotechs industry which returned 10.9% over the past year.
Return vs Market: PDSB exceeded the US Market which returned 15.3% over the past year.
Price Volatility
| PDSB volatility | |
|---|---|
| PDSB Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in US Market | 14.2% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: PDSB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: PDSB's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 26 | Frank Bedu-Addo | https://www.pdsbiotech.com |
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma.
PDS Biotechnology Corporation Fundamentals Summary
| PDSB fundamental statistics | |
|---|---|
| Market Cap | US$160.82m |
| Earnings (TTM) | -US$47.76m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.4x
P/E RatioIs PDSB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PDSB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$47.76m |
| Earnings | -US$47.76m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.55 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 71.7% |
How did PDSB perform over the long term?
See historical performance and comparison